To get semaglutide for weight loss, you need a prescription from a licensed clinician. You typically qualify with a BMI of 30 or higher, or 27 or higher with a weight-related condition. The process involves a medical evaluation, lab work, and an ongoing monitoring plan. This guide covers every step — from eligibility to prescription to what to expect at your first appointment.
What is semaglutide and why does it require a prescription?
Semaglutide is a GLP-1 receptor agonist — a class of medications that mimic glucagon-like peptide-1, a hormone naturally released after eating. By activating GLP-1 receptors in the brain and gut, semaglutide slows gastric emptying, reduces appetite, and influences the reward pathways that drive cravings.
In the United States, semaglutide is the active ingredient in three FDA-approved products:
| Brand name | FDA-approved indication | Form | Starting dose |
|---|---|---|---|
| Wegovy® | Chronic weight management | Weekly injection or daily tablet (as of Jan 2026) | 0.25 mg/week injection or 1.5 mg/day tablet |
| Ozempic® | Type 2 diabetes (off-label for weight loss) | Weekly injection | 0.25 mg/week |
| Rybelsus® | Type 2 diabetes (off-label for weight loss) | Daily oral tablet | 3 mg/day |
Because semaglutide has significant physiological effects — including a boxed warning about thyroid C-cell tumors in animal studies — it is a prescription medication. No version is legally available without a valid prescription from a licensed U.S. clinician.
Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Your clinician will screen for these conditions before prescribing.
For a full overview of how semaglutide works and what to expect from treatment, see: Semaglutide for Weight Management: Evidence-Based Dosing, Risks, and Expectations — Advanced TRT Clinic.
Do I qualify for a semaglutide prescription?
Eligibility is determined by a licensed clinician based on your individual health history, but the following criteria from Wegovy®'s FDA prescribing information provide a starting framework:
Weight-related conditions that may qualify you at BMI ≥27
- Type 2 diabetes or prediabetes
- Hypertension (high blood pressure)
- Dyslipidemia (high LDL cholesterol or triglycerides)
- Obstructive sleep apnea
- Established cardiovascular disease
- Non-alcoholic fatty liver disease (NAFLD / MASH)
Even if you meet the BMI criteria, your prescribing clinician will also review your full medical history, current medications, kidney and liver function, and any contraindications. Eligibility is not automatic — it requires a complete clinical evaluation.
How to get semaglutide: step-by-step
The path from “I'm interested” to “prescription in hand” typically follows four stages. Understanding each one helps you prepare — and avoid the common mistakes that delay or derail access.
Step 1: Complete a medical intake form
Whether you visit a clinic in person or use a telehealth platform, the process begins with a structured health intake. You will typically be asked about your weight history, previous weight-loss attempts, current medications, and any personal or family history of thyroid cancer or MEN2.
Step 2: Consultation with a licensed clinician
A physician, nurse practitioner, or physician assistant will review your intake, confirm your BMI and any qualifying conditions, and assess whether semaglutide is clinically appropriate for you. This consultation may be in person or conducted via telehealth in states where that is permitted for this medication.
Step 3: Lab work
Most responsible prescribers require baseline labs before starting semaglutide. A standard panel typically includes a metabolic panel (kidney and liver function), HbA1c or fasting glucose, lipid panel, and thyroid function. These results inform dosing decisions and identify any pre-existing conditions that could affect safety.
Step 4: Prescription, dispensing, and dose escalation
Wegovy injection starts at 0.25 mg once weekly for the first four weeks, escalating by 0.25 mg every four weeks until the maintenance dose of 2.4 mg is reached. The oral Wegovy tablet (approved December 2025) starts at 1.5 mg daily, escalating to a maintenance dose of 25 mg daily over approximately 12 weeks. Your clinician will determine the appropriate formulation and escalation pace based on your tolerability and response.
Where can you get a semaglutide prescription?
There are three main pathways to a semaglutide prescription in the U.S., each with different tradeoffs in cost, convenience, and clinical depth:
| Pathway | Who it suits | Typical cost of visit | Monitoring depth |
|---|---|---|---|
| Primary care physician | Established patients with a GP relationship | Co-pay / insurance | High |
| Endocrinologist / obesity specialist | Complex cases, metabolic conditions | Co-pay / insurance | High |
| Medically supervised weight-loss clinic | Patients seeking structured, integrated programmes | Varies by programme | High |
| Telehealth / online clinic | Convenience-focused; limited in-person access | $0–$200/visit | Moderate |
Our clinical team provides comprehensive metabolic evaluations that include hormone panel review alongside GLP-1 eligibility assessment. For many patients, optimising hormonal balance alongside weight management therapy produces better long-term outcomes. Learn about our medically supervised weight loss programmes →
Semaglutide vs tirzepatide: which is right for you?
Many patients asking how to get semaglutide are also weighing whether tirzepatide (Zepbound® / Mounjaro®) might be a better fit. Both are GLP-1-based medications, but they differ in mechanism and average outcomes.
Both medications have broadly similar GI side-effect profiles, but trial data suggest tirzepatide produces greater average weight loss at comparable tolerability. The right choice depends on your medical history, cost and coverage, and clinician assessment. For a deeper comparison, see: Tirzepatide Weight Loss Side Effects: Complete Guide — Advanced TRT Clinic.
Cost, insurance, and savings programmes
Cost is one of the most common barriers patients mention when asking how they can get semaglutide for weight loss. Here is a realistic picture as of early 2026:
- Wegovy injection (brand-name, no insurance): approximately $1,300–$1,600 per month at list price.
- Wegovy oral tablet (brand-name, no insurance): pricing structures are still developing following the January 2026 U.S. launch.
- NovoCare savings programme: commercially insured patients may pay as little as $25 per month; self-paying new patients were eligible for introductory pricing on starter doses through March 2026 (check current availability at novocare.com).
- Medicare / Medicaid: coverage for weight management specifically remains limited in many plans; cardiovascular-indication coverage is more widely available for eligible patients.
- Employer insurance: coverage varies significantly; prior authorisation is common and may require documentation of BMI, comorbidities, and previous weight-loss attempts.
Some patients encounter compounded semaglutide through online sources at lower prices. These products are not FDA-approved, have not been evaluated for safety or efficacy, and the FDA has issued specific guidance on associated risks. If cost is a barrier, discuss manufacturer savings programmes with your clinician before seeking unregulated alternatives.
What to expect after starting semaglutide
Understanding the realistic timeline helps patients stay on track through the initial weeks, when side effects are most noticeable and results are not yet visible.
- Week 1–4: Reduced appetite is often noticeable early. Nausea, a feeling of fullness, and mild GI discomfort are most common at the starting dose. Most patients tolerate 0.25 mg well.
- Week 4–12: Dose escalation phase. GI side effects may recur briefly with each increase. Weight loss begins to become measurable for many patients.
- Month 3–6: Clinically meaningful weight loss is typically established. Lab monitoring at 12 weeks helps confirm metabolic response and guides dose decisions.
- Month 6–18: Average weight reduction of approximately 10–15% in most clinical trial populations at this stage, depending on dose reached and adherence [1].
Most GI side effects are dose-dependent and time-limited. Eating smaller, lower-fat meals, staying well hydrated, and not rushing through dose escalation are the most consistently effective strategies. Contact your prescriber before adjusting your dose independently.
For a detailed side-effect guide, including management strategies and who should not use semaglutide, see: Semaglutide for Weight Management: Evidence-Based Dosing, Risks, and Expectations — Advanced TRT Clinic.
This article is for informational purposes only and does not constitute medical advice. Semaglutide is a prescription medication. Always consult a licensed healthcare professional before starting, stopping, or adjusting any medication or therapy. Results may vary.
